Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of ANV419 as Monotherapy or in Combination With Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cutaneous Melanoma (OMNIA-1)

NCT05578872 is registered in ClinicalTrials.gov with Anaveon AG as lead sponsor.

NCT NCT05578872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05578872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of ANV419 as Monotherapy or in Combination With Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cutaneous Melanoma (OMNIA-1)
Lead sponsor
Anaveon AG
Phase
Phase 1/2
Overall status
Completed
Start date
December 16, 2022
Completion date
August 1, 2024
Enrollment
29 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

adult disease, advanced solid tumor, cutaneous melanoma, melanoma (skin), metastatic melanoma